September 18, 2026 Release Highlights Copied
Practice Insights announces the implementation of technical fixes within the application to support Merit-Based Incentive Payment System (MIPS) requirements.
Advance Care Planning Dashboards
Starting Monday, Sept. 21, 2026, the Advance Care Planning Performance and Advance Care Planning Activities Dashboards will be updated with final data from Q2 2026.
Status of Dashboard Updates for 2026
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2026 requirements.
The following measures have been fully updated for the 2026 measure year:
| Measure Number | Description |
| MIPS Quality Measures Dashboard | |
| MIPS #001 | Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure) |
| MIPS #047 | Advance Care Plan |
| MIPS #134 | Preventive Care Screening: Screening for Depression and Follow-Up Plan |
| MIPS #143 | Pain Intensity Quantified |
| MIPS #144 | Pain Care Plan |
| MIPS #226 | Tobacco Screening and Cessation |
| MIPS #236 | Controlling High Blood Pressure |
| MIPS #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| MIPS#450 | Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer |
| MIPS #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| MIPS #457 | Proportion Admitted in Hospice for Less Than 3 Days (Inverse Measure) |
| MIPS #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| PIMSH #1 | Advance Care Planning in Metastatic Disease |
| PIMSH #10 | Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #17 | Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure) |
| PIMSH #19 | Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Inverse Measure) |
| PIMSH #20 | PIMSH 20: Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents |
| PIMSH #21 | Screening and Achieving Resolution or Improvement of Distress for Cancer Care |
| EOM Performance Measures Dashboard | |
| EOM-4A | Pain Intensity Quantified |
| EOM-4B | Pain Care Plan |
| EOM-5 | Preventive Care Screening: Screening for Depression and Follow-Up Plan |